Lowest-Rated StocksLowest-RatedNYSE:BAX Baxter International (BAX) Stock Price, News & Analysis $31.91 +0.43 (+1.37%) Closing price 03:59 PM EasternExtended Trading$32.13 +0.22 (+0.70%) As of 05:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About Baxter International Stock (NYSE:BAX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Baxter International alerts:Sign Up Key Stats Today's Range$31.09▼$32.2750-Day Range$28.63▼$33.7152-Week Range$28.33▼$44.01Volume7.35 million shsAverage Volume5.09 million shsMarket Capitalization$16.29 billionP/E Ratio159.56Dividend Yield2.13%Price Target$40.45Consensus RatingHold Company OverviewBaxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories. It also provides administrative sets; adhesion prevention products; inhaled anesthesia; drug compounding; chronic and acute dialysis therapies and services, including peritoneal dialysis (PD), hemodialysis (HD), continuous renal replacement therapies (CRRT), and other organ support therapies. The company's products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic products; and a collaborative research agreement with Miromatrix Medical Inc. aiming to advance care for patients with acute liver failure. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.Read More… Baxter International Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks94th Percentile Overall ScoreBAX MarketRank™: Baxter International scored higher than 94% of companies evaluated by MarketBeat, and ranked 55th out of 935 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.1 / 5Analyst RatingHold Consensus RatingBaxter International has received a consensus rating of Hold. The company's average rating score is 2.18, and is based on 3 buy ratings, 7 hold ratings, and 1 sell rating.Amount of Analyst CoverageBaxter International has only been the subject of 2 research reports in the past 90 days.Read more about Baxter International's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth34.97% Earnings GrowthEarnings for Baxter International are expected to grow by 34.97% in the coming year, from $1.83 to $2.47 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Baxter International is 159.56, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 111.60.Price to Earnings Ratio vs. SectorThe P/E ratio of Baxter International is 159.56, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 89.05.Price to Earnings Growth RatioBaxter International has a PEG Ratio of 9.88. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioBaxter International has a P/B Ratio of 1.91. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Baxter International's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.51% of the outstanding shares of Baxter International have been sold short.Short Interest Ratio / Days to CoverBaxter International has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Baxter International has recently decreased by 2.13%, indicating that investor sentiment is improving. Dividend1.7 / 5Dividend StrengthWeak Dividend YieldBaxter International pays a meaningful dividend of 2.19%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthBaxter International does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Baxter International is 340.02%. Payout ratios above 75% are not desirable because they may not be sustainable.Dividend SustainabilityBased on earnings estimates, Baxter International will have a dividend payout ratio of 27.53% next year. This indicates that Baxter International will be able to sustain or increase its dividend.Read more about Baxter International's dividend. Sustainability and ESG4.0 / 5Environmental Score-1.95 Percentage of Shares Shorted2.51% of the outstanding shares of Baxter International have been sold short.Short Interest Ratio / Days to CoverBaxter International has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Baxter International has recently decreased by 2.13%, indicating that investor sentiment is improving. News and Social Media2.3 / 5News Sentiment0.13 News SentimentBaxter International has a news sentiment score of 0.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.64 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Baxter International this week, compared to 8 articles on an average week.Search Interest14 people have searched for BAX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows9 people have added Baxter International to their MarketBeat watchlist in the last 30 days. This is an increase of 125% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Baxter International insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.22% of the stock of Baxter International is held by insiders.Percentage Held by Institutions90.19% of the stock of Baxter International is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Baxter International's insider trading history. Receive BAX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Baxter International and its competitors with MarketBeat's FREE daily newsletter. Email Address BAX Stock News HeadlinesBaxter International Inc (BAX) Announces Fourth-Quarter 2024 Financial Results Conference CallJanuary 22 at 5:28 PM | gurufocus.comEarnings Preview: What To Expect From Baxter International's ReportJanuary 21 at 4:20 PM | msn.comStunning Trump Manhattan Project Now UnderwayJust as I predicted, President Trump announced his #1 move during his first 100 days... His allies are calling it Trump’s Manhattan Project.January 22, 2025 | Banyan Hill Publishing (Ad)Heparin Market to Grow by USD 3.34 Billion (2024-2028), Driven by Rising Prevalence of Coagulation Disorders; AI-Powered Market Evolution - TechnavioJanuary 16, 2025 | finance.yahoo.comBaxter price target lowered to $42 from $45 at Evercore ISIJanuary 3, 2025 | markets.businessinsider.comBaxter International Inc. stock underperforms Thursday when compared to competitors despite daily gainsJanuary 2, 2025 | marketwatch.comShould We Be Cautious About Baxter International Inc.'s (NYSE:BAX) ROE Of 1.6%?December 31, 2024 | finance.yahoo.comHow Is The Market Feeling About Baxter Intl?December 25, 2024 | benzinga.comSee More Headlines BAX Stock Analysis - Frequently Asked Questions How have BAX shares performed this year? Baxter International's stock was trading at $29.16 at the start of the year. Since then, BAX shares have increased by 9.4% and is now trading at $31.9110. View the best growth stocks for 2025 here. How were Baxter International's earnings last quarter? Baxter International Inc. (NYSE:BAX) posted its quarterly earnings results on Friday, November, 8th. The medical instruments supplier reported $0.80 EPS for the quarter, topping the consensus estimate of $0.78 by $0.02. Baxter International's revenue was up 3.8% compared to the same quarter last year. Read the conference call transcript. Does Baxter International have any subsidiaries? Baxter International subsidiaries include Cheetah Medical, ApaTech Limited, Baxter AO, Baxter Belgium SPRL, Baxter (China) Investment Co. Ltd, Baxter Company Ltd, Baxter Corporation (Canada), and more. Who are Baxter International's major shareholders? Baxter International's top institutional investors include Centre Asset Management LLC (0.05%), Nisa Investment Advisors LLC (0.02%), Pacer Advisors Inc. (0.01%) and SG Americas Securities LLC. Insiders that own company stock include Jeanne K Mason, Albert P L Stroucken, Jacqueline Kunzler and Brian Stevens. View institutional ownership trends. How do I buy shares of Baxter International? Shares of BAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Baxter International own? Based on aggregate information from My MarketBeat watchlists, some other companies that Baxter International investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Exxon Mobil (XOM), Chevron (CVX), JPMorgan Chase & Co. (JPM) and Intel (INTC). Company Calendar Last Earnings11/08/2024Ex-Dividend for 1/2 Dividend11/29/2024Dividend Payable1/02/2025Today1/22/2025Next Earnings (Estimated)2/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment Current SymbolNYSE:BAX CUSIP07181310 CIK10456 Webwww.baxter.com Phone(224) 948-2000Fax224-948-1813Employees60,000Year Founded1931Price Target and Rating Average Stock Price Target$40.45 High Stock Price Target$54.00 Low Stock Price Target$30.00 Potential Upside/Downside+28.4%Consensus RatingHold Rating Score (0-4)2.18 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)$0.20 Trailing P/E Ratio157.48 Forward P/E Ratio16.40 P/E Growth9.88Net Income$2.66 billion Net Margins0.77% Pretax Margin-0.50% Return on Equity18.30% Return on Assets5.43% Debt Debt-to-Equity Ratio1.31 Current Ratio1.43 Quick Ratio1.09 Sales & Book Value Annual Sales$14.81 billion Price / Sales1.09 Cash Flow$5.33 per share Price / Cash Flow5.91 Book Value$16.69 per share Price / Book1.89Miscellaneous Outstanding Shares510,590,000Free Float509,465,000Market Cap$16.08 billion OptionableOptionable Beta0.59 Social Links 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report This page (NYSE:BAX) was last updated on 1/22/2025 by MarketBeat.com Staff From Our PartnersMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is ...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredDid You See Trump’s Manhattan Project Bombshell?This secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredKamala’s final humiliation Now, for the first time, I’m going to share these ten investments publicly – the same ones I’ve discussed behi...Porter & Company | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredMust-See: 5-Second Trump PredictionPresident Trump's prediction is about to become a reality... Opening a rare window of opportunity for you t...InvestorPlace | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Baxter International Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Baxter International With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.